Androgen receptor molecular biology and potential targets in prostate cancer
- 8 June 2010
- journal article
- review article
- Published by SAGE Publications in Therapeutic Advances in Urology
- Vol. 2 (3) , 105-117
Abstract
The androgen receptor (AR) is a key transcriptional regulator and therapeutic target in prostate cancer. During androgen deprivation therapy to treat metastatic prostate cancer, surviving cells acquire increased AR signaling through a variety of mechanisms, one of which is enhanced interactions with AR coactivators. One recently identified AR-specific coregulator expressed only in human and nonhuman primates is the melanoma antigen gene protein-A11 (MAGE-11). MAGE-11 increases AR transcriptional activity through direct interactions with AR and other coactivators, and its levels increase during prostate cancer progression to castration-recurrent growth. The MAGE-11 gene is located at Xq28 on the human X chromosome as part of an X-linked MAGE gene family of cancer—testis antigens. MAGE-11 stabilizes AR when androgen levels are low, and functions in a transcriptional hub to promote AR-mediated gene activation. The evolutionary development and organization of the MAGE-11 gene within the cancer—testis antigen family suggests that MAGE-11 provides a gain-of-function to AR among primates in both normal physiology and cancer, and may serve as a therapeutic target in the treatment of advanced prostate cancer.Keywords
This publication has 125 references indexed in Scilit:
- Partners in crime: deregulation of AR activity and androgen synthesis in prostate cancerTrends in Endocrinology & Metabolism, 2010
- CT-X antigen expression in human breast cancerProceedings of the National Academy of Sciences, 2009
- Global discovery of primate-specific genes in the human genomeProceedings of the National Academy of Sciences, 2009
- Booster vaccination of cancer patients with MAGE-A3 protein reveals long-term immunological memory or tolerance depending on primingProceedings of the National Academy of Sciences, 2008
- Vaccination with an NY-ESO-1 peptide of HLA class I/II specificities induces integrated humoral and T cell responses in ovarian cancerProceedings of the National Academy of Sciences, 2007
- Genome-wide analysis of estrogen receptor binding sitesNature Genetics, 2006
- MAGE-A tumor antigens target p53 transactivation function through histone deacetylase recruitment and confer resistance to chemotherapeutic agentsProceedings of the National Academy of Sciences, 2006
- Small-molecule inhibitors of protein–protein interactions: progressing towards the dreamNature Reviews Drug Discovery, 2004
- DNA methylation in cancer: too much, but also too littleOncogene, 2002
- A mutation in the ligand binding domain of the androgen receptor of human INCaP cells affects steroid binding characteristics and response to anti-androgensBiochemical and Biophysical Research Communications, 1990